Picture of Fresenius SE & Co KGaA logo

FRE Fresenius SE & Co KGaA Share Price

0.000.00%
de flag iconLast trade - 00:00
HealthcareBalancedLarge CapSuper Stock

Momentum

Relative Strength (%)
1m+10.24%
3m-3.31%
6m-7.22%
1yr+0.06%
Volume Change (%)
10d/3m-2.14%
Price vs... (%)
52w High-13.84%
50d MA+5.35%
200d MA-0.93%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)8.57
PEG Ratio (f)0.35
EPS Growth (f)32.37%
Dividend Yield (f)3.62%
Valuation (ttm)IndustryMarket
Price to Book Value0.8
Price to Tang. Book10.99
Price to Free Cashflow4.61
Price to Sales0.68
EV to EBITDA12.04

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital3.18%
Return on Equity1.79%
Operating Margin5.13%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total Revenue€m35,40936,27737,52021,53222,29925,256.6327,556.21-7.83%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+34.02-5.83-21.5-11.2-10.04+42.75+15.73n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Fresenius SE & Co KGaA EPS forecast chart

Profile Summary

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion therapies. It also supplies hospitals with medical devices and products of transfusion technology. Fresenius Helios is a private hospital operator, with over 130 facilities in Germany, including maximum care hospitals and rehabilitation centers and, through Quironsalud, over 80 hospitals and outpatient centers, as well as approximately 300 Occupational Risk Prevention Centers in Spain. Fresenius Vamed manages projects and provides services for health care facilities worldwide, from development and turnkey construction to maintenance and total operational management.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
January 28th, 2011
Public Since
December 18th, 1986
No. of Employees
193,865
Sector
Healthcare Providers & Services
Industry
Healthcare
Exchange
de flag iconXETRA
Shares in Issue
563,237,277
Blurred out image of a map
Address
Else-Kroener-Str. 1, BAD HOMBURG, 61352
Web
https://www.fresenius.com/
Phone
+49 61726080
Contact
Markus Georgi
Auditors
KPMG AG Wirtschaftsprufungsgesellschaft

FRE Share Price Performance

Upcoming Events for FRE

Q1 2024 Fresenius SE & Co KGaA Earnings Release

Q1 2024 Fresenius SE & Co KGaA Earnings Call

Fresenius SE & Co KGaA Annual Shareholders Meeting

Q2 2024 Fresenius SE & Co KGaA Earnings Release

Q2 2024 Fresenius SE & Co KGaA Earnings Call

FAQ